Clinical Guidelines > Current Guidelines >

BHIVA and BIA guidelines for the treatment of Opportunistic Infection in HIV-seropositive Individuals 2011

Introduction

Advances in the treatment of HIV infection with antiretroviral therapy have led to dramatic reductions in opportunistic infections and death. However, late presentation of HIV remains a problem and is a significant contributory cause to death in HIV-seropositive persons in the UK [1]. Furthermore, a recent UK Health Protection Agency (HPA) analysis showed that of 46 700 patients with diagnosed HIV, 19% had CD4 counts o200 cells/mL [2] and therefore remain at significant risk of opportunistic infection.

These guidelines have been drawn up to help physicians investigate and manage HIV-seropositive patients suspected of, or having an opportunistic infection (OI). They are primarily intended to guide practice in the UK and related health systems.


Downloads

British HIV Association and British Infection Association Guidelines for the Treatment of Opportunistic Infection in HIV-seropositive Individuals 2011

Treatment of Opportunistic Infection in HIV-seropositive Individuals (2011)


Writing group

Dr Mark Nelson (Co-chair), Prof David Dockrell (Co-chair), Dr Simon Edwards (Co-chair), Dr Brian Angus, Dr Simon Barton, Dr Nick Beeching, Prof Colm Bergin, Dr Marta Boffito, Dr Ronan Breen, Dr Jonathan Cartledge, Dr Susan Clarke, Dr Martin Fisher, Dr Andrew Freedman, Prof Brian Gazzard, Dr Alison Grant, Dr Julia Greig, Dr Rachael Jones, Prof Saye Khoo, Prof Clifford Leen, Dr Marc Lipman, Dr Hadi Manji, Prof Robert Miller, Miss Suzanne Mitchell, Dr Ed Ong, Dr Anton Pozniak, Dr Matthias Schmid, Miss Marianne Shiew, Prof Mervyn Singer, Dr Ed Wilkins, Dr Ian Williams, Dr Chris Wood, Ms Rosy Weston

UK-CAB (community) members are involved in the writing and/or proofreading of each chapter, and where not listed as authors are the UK-CAB members of the Guidelines Subcommittee.


Peer review

The guidelines were peer reviewed by Professor Mauro Schechter, Federal University of Rio de Janeiro, Brazil, Professor Jürgen Rockstroh, University of Bonn, Germany, and Professor Christine Katlama, Sorbonne University, Paris, France.


Reference

HIV Medicine (2011), 12 (Suppl. 2), 1-140.